125 results on '"Mariette , Xavier"'
Search Results
2. Primary Sjögrenʼs Syndrome
3. The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy
4. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study
5. Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjögren’s syndrome
6. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
7. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
8. Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögrenʼs Syndrome
9. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment
10. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment
11. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE
12. Guidelines for treatment of primary Sjögren’s syndrome: a first useful stone but still much to do
13. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
14. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
15. 07.01 A multi-parameter response prediction model for rituximab in rheumatoid arthritis
16. A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren’s syndrome
17. Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?
18. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
19. Clinical relevance of RORγ positive and negative subsets of CD161+CD4+ T cells in primary Sjögren’s syndrome
20. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögrenʼs syndrome: A consensus and data-driven methodology involving three international patient cohorts
21. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögrenʼs Syndrome: A Consensus and Data‐Driven Methodology Involving Three International Patient Cohorts
22. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force
23. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology’s ORA registry
24. X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögrenʼs Syndrome
25. Reply
26. Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögrenʼs Syndrome
27. Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögrenʼs syndrome
28. Germline variation of TNFAIP3 in primary Sjögrenʼs syndrome-associated lymphoma
29. Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjögren syndrome: comparison of different kits
30. Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A French Nationwide Study of Ninety-Two Patients
31. IgG4-related disease associated with renal microaneurysms and polycythaemia
32. Renal involvement in primary Sjögren syndrome
33. Defining disease activity states and clinically meaningful improvement in primary Sjögrenʼs syndrome with EULAR primary Sjögrenʼs syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)
34. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study)
35. Characterization of systemic disease in primary Sjögrenʼs syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements
36. Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study
37. Anti–Porphyromonas gingivalis Antibodies in Rheumatoid Arthritis: Comment on the Article by Seror et al
38. Development of the Sjögren’s Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy
39. Genetic contribution of DKK-1 polymorphisms to RA structural severity and DKK-1 level of expression
40. Association of Anti–Porphyromonas gingivalis Antibody Titers With Nonsmoking Status in Early Rheumatoid Arthritis: Results From the Prospective French Cohort of Patients With Early Rheumatoid Arthritis
41. Validation of EULAR primary Sjögrenʼs syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)
42. Efficacy and safety of belimumab in primary Sjögrenʼs syndrome: results of the BELISS open-label phase II study
43. Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management
44. The IRF5–TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share
45. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial
46. Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry
47. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial
48. Use of Whole-Blood Transcriptomic Profiling to Highlight Several Pathophysiologic Pathways Associated With Response to Rituximab in Patients With Rheumatoid Arthritis: Data From a Randomized, Controlled, Open-Label Trial
49. Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome: The JOQUER Randomized Clinical Trial
50. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.